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H I G H L I G H T S
• In NSTEMI patients, there was a trans-cardiac decrease in CRP across the myocardium.• This decrease was irrespective of time of presentation, infarct size and culprit lesion location.• There was no trans-lesional gradient across the culprit coronary artery lesion.• Both injured and non-injured myocardium contributes to the decrease in CRP.
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A B S T R A C T
Background and aims: Inflammation has become a key element in cardiovascular disease, and recently, new anti-
inflammatory interventions have shown promising results. In this context, CRP levels have been thoroughly
studied in vitro and in animals, but studies in humans are scarce and insights into its release, site(s) of production
and uptake are not uniform.
Methods: We performed a biomarker study with multi-site sampling in the coronary circulation, in non-ST
elevation MI (NSTEMI) patients with coronary angiography and right-sided catheterisation. Trans-lesional
gradients were obtained by sampling distal to the culprit lesion, in patients with a suitable anatomy. To asses
trans-cardiac gradients, blood was sampled from the systemic circulation, coronary sinus (CS) and great cardiac
vein. Concentrations of CRP were measured with a high-sensitivity assay.
Results: In 42 patients, a median systemic venous CRP concentration of 4.97mg/L was observed. There was no
evidence of a trans-lesional gradient (4.59mg/L versus 4.56mg/L, p=0.278; n= 14). A significant decrease in
CRP concentration was observed between systemic arterial and CS samples (4.88mg/L versus 4.44mg/L;
p < 0.001; n=42). This trans-cardiac gradient was irrespective of time of presentation, infarct size and culprit
lesion location. The gradient was not only driven by blood that ran through the injured myocardium, but also by
lower CRP concentrations in the coronary veins that drain non-infarcted myocardium.
Conclusions: In the context of NSTEMI, we observed a trans-cardiac decrease in CRP, which may indicate the first
human in vivo proof of a net CRP uptake by the myocardium, with a role for CRP both in the injured and adjacent
myocardium.
1. Introduction
The inflammatory process has become a key issue of interest in the
development of atherosclerosis and the progression to athero-
thrombosis [1–3]. Despite clear associations between C-reactive protein
(CRP) and the risk of future events in coronary artery disease [4,5], the
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role of CRP in the acute phase of myocardial infarction still requires
further investigation.
In general, there is consensus that CRP production mainly occurs in
the hepatocytes in response to an extra-hepatic stimulus [6]. Moreover,
systemic CRP levels are generally higher in myocardial infarction (MI)
patients than in stable coronary artery disease [7]. Appreciating that
CRP binds to injured cells and activates inflammation, an evident role
for CRP was suggested in the aftermath of MI [7]. Several studies fo-
cused on coronary CRP levels, varying from trans-lesional assessments
(proximal and distal to the culprit lesion) [8–12] to studies on trans-
cardiac gradients, i.e. from the aorta to the coronary sinus (CS)
[12–17].
Despite evidence of high CRP mRNA content in unstable plaques
[13] and a trans-lesional increase of CRP in patients with unstable
angina [12], other studies on trans-lesional concentrations generally
reported no evidence of a gradient in acute coronary syndrome (ACS)
[9–11]. The few studies on trans-cardiac gradients showed conflicting
results and varied in study design and population [12–17]. Although
several histopathological studies have shown that CRP is deposited in
infarcted regions of the myocardium [18,19], most studies on trans-
cardiac gradients did not report on the association between the extent
of myocardial damage and CRP changes. This may be of particular
importance, as previous studies have suggested that the trans-cardiac
gradient of inflammatory markers depends on the presence or absence
of injured myocardium [20,21]. In this context, a more detailed study
could improve insight into the role of CRP in MI patients.
We therefore conducted a multi-site coronary sampling study in
non-ST elevation MI (NSTEMI) patients to assess both trans-lesional and
trans-cardiac CRP gradients. In the abovementioned context, we fo-
cussed on the impact of single versus multivessel disease, infarct size
and had specific interest for injured versus non-injured myocardium on
changes in CRP levels across the heart.
2. Patients and methods
2.1. Patient population
The TRans-cardiac Assessment of Myocardial Injury and Coronary
Inflammation (TRAMICI) study is a prospective mechanistic study
performed in the catheterisation laboratory of the Radboud University
Medical Center (Radboudumc, Nijmegen, The Netherlands) in patients
presenting with a NSTEMI. Patients from the Radboudumc and three
referring centers were eligible if they presented early after symptom
onset, were diagnosed with a NSTEMI and had evidence of elevated (i.e.
above the 99th percentile reference limit of normal) and rising cardiac
troponin levels based on conventional troponin assays used in the re-
spective hospitals. Subsequently, patients were referred for a clinically
indicated coronary angiography (CAG) in the Radboudumc. Upon
identification of the culprit coronary artery by the interventional car-
diologist, patients were included and study procedures were started.
Exclusion criteria were: an indication for emergency percutaneous
coronary intervention (PCI) at presentation, prior PCI or CABG (< 3
months), prior anginal complaints (< 3 weeks), killip class III and IV,
other suspected life-threatening disease at presentation, peripheral ar-
terial disease (Fontaine III and IV), presence of a pacemaker, main stem
stenosis (> 50%), anomalous coronary anatomy, serum
creatinine> 150 μmol/L, systemic infection, hematologic disorder or
treatment with an immunosuppressive agent, treatment with NSAID or
antibiotics. The presence of collateral coronary artery filling was con-
sidered a relative exclusion criterion. After obtaining oral informed
consent prior to the procedure, participants provided written informed
consent. The protocol was approved by the local ethical committee and
study procedures were in accordance with the Declaration of Helsinki.
2.2. Study procedures
The coronary venous anatomy was recorded during CAG by filming
the complete washout of contrast dye. Access to the CS was gained by
means of a right-sided catheterisation procedure. For cannulation and
blood sampling of the coronary venous system, a Terumo wire (Terumo
Europe NV, Leuven, Belgium) and CHAMP multipurpose catheter
(Medtronic, Santa Rosa, CA, USA) were used, respectively.
Coronary venous system samples: After cannulation of the CS, the
CHAMP catheter was advanced into the great cardiac vein (GCV). This
vein primarily drains blood from the anteroseptal walls [22]. Conse-
quently, in patients with a culprit lesion in the left anterior descending
artery (LAD), a selective blood sample from this site represents bio-
marker concentrations in blood that just ran through injured myo-
cardium. Alternatively, in patients with a non-LAD culprit lesion, a
selective blood sample from this site represents biomarker concentra-
tions in a vein that drains blood from myocardium not supplied by the
infarct related artery. After sampling in the GCV, the catheter was
pulled back towards the CS at the point where the middle cardiac vein
merges with the CS. Being the rendezvous point of all blood that passed
the myocardium, the CS sample represents the trans-cardiac gradient.
Blood sampling was performed according to the following protocol
driven procedures. First, the position of the catheter was confirmed
using contrast dye, after which the catheter was flushed. Second, there
was a waiting period to allow for sufficient blood reflux. Then, a first
blood sample of 3–4mL was drawn to perform blood gas analysis, as a
double check of the catheter position. Subsequently, the blood sample
of interest was obtained. Fig. 1 illustrates the different sampling sites
within the coronary venous system.
Systemic blood samples: After removal of the CHAMP catheter from
the coronary venous system, systemic blood samples were obtained
from the femoral venous and arterial sheaths.
Culprit artery samples: Patients with a suitable anatomy, and in
whom the preferred revascularisation strategy was PCI, were eligible
for an additional sample from the culprit coronary artery distal to the
culprit lesion. Prior to the PCI, a guiding catheter was inserted in the
ostium of the culprit coronary artery. A wire was then advanced beyond
the culprit lesion followed by an over-the-wire balloon- (MAVERICK) or
microcatheter (Boston Scientific, Marlborough, MA, USA). After re-
moval of the wire while keeping the catheter in place, blood was as-
pirated distal from the culprit lesion.
Follow-up samples: Finally, at 6 and 12 h post-procedure, additional
venous samples were obtained from an antecubital vein.
All collected blood samples were divided over serum and plasma
tubes, centrifuged, aliquoted and stored at −80 °C until thawed for
further analysis.
2.3. Coronary angiogram analysis
All angiograms were reviewed by a second team of doctors (SD, GC
and HG), unaware of biomarker analysis. They performed a standar-
dised evaluation of left ventriculography for wall motion abnormalities,
lesion characteristics, and coronary flow to identify the culprit lesion.
Lesion severity was based on visual estimation. In case of a discrepancy
with regard to the decision on the culprit artery between the inter-
ventional cardiologist and the second team, data were analysed by a
third cardiologist (MB), unaware of any former decision on culprit lo-
cation. When the third reviewer agreed with either of the two previous
teams, the location of the culprit artery was decided on. If not, the
patient was excluded from the present analysis.
2.4. Measurement of biomarkers
Biomarker analysis was performed at the clinical chemistry de-
partment in the Isala Clinics (Isala Clinics, Zwolle, The Netherlands)
and the Maastricht University Medical Center+ (MUMC, Maastricht,
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The Netherlands). The biomarkers involved in the current analysis are:
high-sensitivity CRP, high-sensitivity cardiac troponin T (hs-cTnT), CK-
MB and albumin. All assays were provided by Roche Diagnostics, and
analyses performed on a Cobas analyser (Roche, Mannheim, Germany).
With respect to CRP concentrations the lower limit of detection is
0.15 mg/L, and at 0.3 mg/L the coefficient of variation is< 10%. The
hs-cTnT assay has a limit of blank of 3 ng/L and a coefficient of var-
iation of< 10% at 13 ng/L (limit of quantification). With regard to the
CK-MB immunoassay a lower limit of detection of 0.1 ng/mL is re-
ported. Given the well-described correlation between infarct size and
peak CK-MB, this biomarker was chosen to define infarct size in our
population [23]. Patients were divided in small (lower 50th percentile)
and large (upper 50th percentile) MI based on the peak CK-MB con-
centration measured during admission. As for albumin, the measuring
range was 2–100 g/L defined by the limit of detection and the max-
imum of the master curve.
2.5. Statistical analysis
The present analysis on CRP is a prospectively defined secondary
objective of the TRAMICI project, and is performed on a subset of the
entire study population. The total number of participants in TRAMICI
was based on the required number of patients for the primary objective,
with troponin measurements as primary outcome. Continuous data
were analysed for Gaussian distribution and were expressed as medians
with interquartile ranges (IQR). Numerical data were described as a
number with a percentage. Paired data were compared using the
Wilcoxon signed rank test. The Mann-Whitney U test was performed for
comparisons of biomarker concentrations between subgroups of pa-
tients. Fisher's exact test was used for comparison of proportions of
patients. To assess the correlation between the per-patient trans-cardiac
CRP and albumin gradients we calculated the Pearson correlation
coefficient. A p-value less than 0.05 was considered statistically sig-
nificant. All analyses were performed using IBM SPSS Statistics software
(version 22.0, IBM Corp., Armonk, NY, USA).
3. Results
The study population for the current analysis consists of 42 patients
(Supplementary Figure 1). Baseline clinical and angiographic char-
acteristics are shown in Table 1. The median duration of symptoms was
236 (interquartile range: 99–485) minutes, with a median duration of
symptom onset to the start of CAG of 25 (19–35) hours. The median
baseline peripheral venous concentration of hs-cTnT was 175 (91–314)
ng/L, which increased to a median peak concentration of 229
(131–398) ng/L.
3.1. Peripheral CRP concentrations
The CRP concentrations at baseline showed no significant difference
between the arterial and venous samples (4.88 [2.35–10.42] mg/L vs.
4.97 [2.29–10.16] mg/L; p=0.164). The median peripheral venous
CRP concentration increased to 5.35 [2.62–13.11] mg/L (p < 0.001)
at 6 h and to 6.87 [3.32–12.10] mg/L (p < 0.001) at 12 h after the
baseline measurements. At baseline, patients with a large MI had non-
significantly higher CRP concentrations compared to small MI patients
(7.52 [3.44–41.26] mg/L vs. 5.22 [2.06–11.9] mg/L; p=0.170).
3.2. Trans-cardiac gradients
CRP concentrations in the CS and systemic circulation are depicted
in Table 2. A decrease in median CRP concentration was observed
Fig. 1. Schematic view of the coronary venous
system.
LAD: left anterior descending artery. GCV: great
cardiac vein. RCX: ramus circumflex artery. PLV:
posterolateral vein. RCA: right coronary artery. MCV:
middle cardiac vein. SVC: superior caval vein. IVC:
inferior caval vein. The asterixes depict the sampling
sites in the great cardiac vein and coronary sinus.
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between systemic arterial and CS blood (4.88mg/L [2.35–10.42] versus
4.44mg/L [2.14–9.42]; p < 0.001) (see Supplementary Materials for
the individual CRP concentrations). No difference in trans-cardiac
gradient was observed between statin users and statin naive patients
and between aspirin users and aspirin naive patients. In addition, we
assessed trans-cardiac albumin gradients to ascertain whether sample
dilution might have affected the results. Although a median trans-car-
diac albumin decrease of 4.8% was observed, there was no correlation
with the trans-cardiac CRP gradient (correlation coefficient 0.044;
p=0.783). In the patients who showed both a trans-cardiac CRP de-
crease and a trans-cardiac albumin decrease, no correlation was ob-
served between the per-patient trans-cardiac CRP and albumin gra-
dients (correlation coefficient 0.028; p=0.895).
In Fig. 2, the relative changes in CRP concentration are depicted in
the dark grey boxes in relation to time-interval between symptom onset
and blood sampling (2A), infarct size based on peak CK-MB con-
centration (2B), the number of diseased vessels involved (2C), and the
location of the culprit lesion (2D). The observed relative trans-cardiac
decrease in CRP concentration in the overall population was present in
all subgroups. Of the 21 patients with a large MI, five (24%) had a
trans-cardiac increase in CRP concentration. Two of the 21 patients
(10%) with a small MI had a trans-cardiac increase (p=0.410).
3.3. Culprit lesion
In a selected group of 14 patients, blood was obtained from the
culprit coronary artery distal to the culprit lesion. No significant dif-
ference was observed in CRP concentration between the systemic ar-
terial and post-stenotic compartment sample (4.59mg/L [2.07–7.73]
versus 4.56mg/L [2.07–7.90], p=0.278).
3.4. Selective sampling of the great cardiac vein
Patients were categorised according to the infarct related artery,
LAD (n=16) versus non-LAD (n=26; RCA or RCX). As the GCV se-
lectively drains blood from the anteroseptal wall, measurements of CRP
derived from the GCV represent a trans-cardiac gradient across ‘injured’
myocardium for patients with a culprit in the LAD. For patients in the
non-LAD group, the measurements reflect a gradient across ‘non-in-
jured’ myocardium. Concentrations of CRP in the GCV are depicted in
Table 2.
There was a decrease in CRP concentration towards the GCV, which
was only significant in patients with a non-LAD culprit lesion. Relative
changes in CRP towards the GCV are depicted in Fig. 2D (light grey
boxes).
4. Discussion
In this elaborate multi-site coronary sampling study in patients
presenting with an NSTEMI, we showed a significant trans-cardiac de-
crease in CRP from the systemic circulation to the coronary venous
system. At the same time, CRP concentrations across the culprit lesion
were not different from those measured in the systemic circulation. Our
in vivo finding of a trans-cardiac decrease are in line with ex vivo ob-
servation of CRP deposition, and suggest a net uptake at the level of the
myocardial tissue.
In general, systemic CRP concentrations are known to increase after
MI [24]. This corroborates with our CRP concentrations six and 12 h
after the CAG. In view of this, the overall response to myocyte injury in
the setting of NSTEMI is that of CRP production. Besides hepatic se-
cretion, several studies also suggested a role for the coronary plaque as
production site for CRP. This was based on an in vitro study that de-
monstrated CRP production by coronary artery smooth muscle cells
[25]. Moreover, an ex vivo experiment showed the presence of CRP
mRNA in culprit plaques from patients with unstable coronary artery
disease [13]. In accordance with this, it has also been shown that CRP
concentrations increased across the culprit lesion in a group of patients
with unstable angina [12], and across the coronary circulation (aorta to
CS) in another group of patients [13,14]. Based on these observations, it
has been suggested that there is local vascular production in addition to
systemic production. Interestingly, several other studies investigating
trans-lesional gradients did not reproduce an increase of CRP across the
culprit lesion and disputed the finding of local vascular production
[9–11]. Our study, in which a trans-lesional CRP gradient could not be
shown, corroborates with these findings. Additionally, our analyses on
the burden of atherosclerotic disease - as expressed by single versus
multivessel disease - had no influence on the observed trans-cardiac
CRP decrease (Fig. 2). This suggests that the trans-cardiac gradient we
Table 1
Baseline clinical and angiographic characteristics.
All patients n= 42
Age at admission 65 (53–73)
Gender (male) 32 (76%)
Smoking 22 (52%)
Hypertension 21 (50%)
Diabetes mellitus 4 (10%)
Aspirin therapya 14 (33%)
Statin therapy 13 (31%)
History of MI 9 (21%)
History of coronary revascularisation 4 (10%)
hs-cTnT on admission (ng/L) 175 (91–314)
CK-MB on admission (ng/mL) 7.13 (3.0–15.9)
Time between onset complaints and CAG (hours) 25 (19–35)
Duration of anginal symptoms (min) 236 (99–485)
Number of diseased vessels
1 15 (36%)
2 19 (45%)
3 8 (19%)
Culprit artery
RCA 10 (24%)
RCX 16 (38%)
LAD 16 (38%)
Severity culprit stenosis
50–70% 0 (0%)
70–90% 20 (48%)
>90% 22 (52%)
PCI performed 27 (64%)
Values are medians (interquartile range) or numbers (percentage).
MI: myocardial infarction. hs-cTnT: high-sensitivity cardiac troponin T. CK-MB:
creatinin kinase myocardial brain. URL: upper reference limit. CAG: coronary
angiography. RCA: right coronary artery. RCX: ramus circumflex artery. LAD:
left anterior descending artery.
a Every patient received a loading dose of aspirin.
Table 2
CRP concentrations in systemic artery, coronary sinus and great cardiac vein.
Systemic artery CS p-valuea GCV p-valueb
All patients (n= 42) 4.88 (2.35–10.42) 4.44 (2.14–9.42) < 0.001 4.43 (2.23–9.50) <0.001
LAD (n= 16) 4.87 (1.33–12.25) 4.65 (1.36–10.87) 0.003 4.80 (1.45–9.60) 0.134
Non-LAD (n= 26) 4.88 (2.53–10.42) 4.44 (2.31–9.30) 0.002 4.28 (2.39–9.65) 0.003
Concentrations of CRP depicted as medians (IQR) in mg/l. a: comparison between peripheral artery and CS. b: comparison between peripheral artery and GCV.
CS: coronary sinus. GCV: great cardiac vein.LAD: left anterior descending culprit artery. Non-LAD: right coronary artery or ramus circumflex culprit artery.
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observed is mainly driven at the level of the myocardium. Interestingly,
and in contrast to the multi-site sampling procedures in our study, the
majority of studies on CRP gradients did not simultaneously assess both
trans-lesional and trans-cardiac gradients, which complicates the in-
tegration of the available study data into a more comprehensive con-
cept. Moreover, it is important to note that, in contrast to cardiac
production, there have also been reports on myocardial CRP uptake in
the setting of myocardial injury. In histopathological studies on myo-
cardial tissue of patients who suffered from fatal ST-elevation MI, it has
consistently been shown that CRP was deposited in the infarcted parts
of the myocardium [18,19,26].
Intriguingly, we are the first to have observed a clear trans-cardiac
decrease in an in vivo setting of NSTEMI patients, which suggests a net
myocardial CRP uptake. From previous reports on the function of CRP,
it is well known that CRP a-specifically binds to injured tissue after
exposure of phosphocholine groups, which appear on the cell mem-
brane of necrotic cells. After binding, CRP activates the complement
system promoting opsonisation [27,28], and therefore acts as an im-
portant pro-inflammatory mediator [19]. CRP provides an early de-
fence mechanism through rapid activation of the innate immune
system. By attracting other inflammatory cytokines, it ultimately plays
a role as an initial step in the healing process of injured tissues [27].
Given the extra-cardiac production in the presence of MI, and appre-
ciating the physiologic function of CRP, binding to damaged myocardial
cells is a plausible explanation for the observed trans-cardiac decrease
in CRP concentrations across the myocardium in the present study.
In contrast to our findings, the majority of studies on trans-cardiac
gradients found no difference, and two reported an increase in CRP
across the heart [12–17]. Appreciating that the reported group effect is
a composite of observed individual increases and decreases, we hy-
pothesised that differences in infarct size between studies may have
contributed to the discrepant findings. Especially, given the previous
evidence that the presence or absence of myocardial injury has an effect
on trans-cardiac gradients of inflammatory markers [20,21]. With re-
gard to the impact of the extent of myocardial injury on our observed
trans-cardiac gradient, we compared patients with a larger-sized MI to
those with a smaller-sized MI according to CK-MB peak concentrations.
On average, we observed a decrease in CRP concentration from the
systemic circulation to the CS for both groups, irrespective of whether
infarct size was based on peak CK-MB, baseline or peak troponin levels
(latter two not reported). Interestingly, in a few patients we saw a trans-
cardiac increase in CRP. Most of these patients were among those with a
larger-sized MI. From this we contemplate that in a different popula-
tion, represented by patients with larger-sized MIs, trans-cardiac gra-
dients might show net increases in CRP concentration more often. Al-
though speculative, this could be one of the explainations for the non-
uniformity of available evidence in ACS [13,14]. Unfortunately, the
majority of previous studies did not report on infarct size and the im-
pact on the trans-cardiac CRP gradients. The only study in acute ST
elevation MI patients, to our knowledge, that performed CRP mea-
surements in CS blood did not observe a trans-cardiac gradient [15].
Notably, the median time-interval between symptom onset and study
procedures was only 3.2 ± 0.5 h, whereas in our study it was 25
[19–35] hours. Importantly, ex vivo examinations of STEMI patients
have shown that the process of CRP uptake occurs between 12 h and 5
days after symptom onset. This time-interval is considered the phase of
polymorphonuclear leukocyte infiltration [18,19]. Probably, and in
contrast to our findings, blood sampling was too early to result in a
Fig. 2. Trans-cardiac gradients of CRP according to subgroups.
Median percentage relative change in CRP with interquartile range. *Significant gradients. (A) Early vs. late presentation: based on time interval between symptom
onset and blood sampling: early (lower 50th percentile) and late (upper 50th percentile). (B) Small MI vs. large MI: patients divided based on peak CK-MB infarct size
in small MI (lower 50th percentile) and large MI (upper 50th percentile). (C) Single vs. multi-vessel disease: patients divided based on the coronary atherosclerotic
burden in single vessel disease (one coronary artery with stenosis> 50%) or multi vessel disease (> 1 coronary artery with stenosis> 50%). (D) LAD vs. non-LAD:
patients divided based on the location of their culprit artery in LAD or non-LAD. Gradient - to coronary sinus: median relative change between systemic arterial and
coronary sinus sample. Gradient - to GCV: median relative change between systemic arterial and great cardiac vein sample. hs-CRP: high sensitivity C-reactive
protein. GCV: great cardiac vein. MI: myocardial infarction. LAD: left anterior descending artery.
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measurable amount of CRP uptake in this study of acute MI patients.
Given the aforementioned aspects, future research investigating in-
flammatory gradients in MI patients should adequately address infarct
size and timing between symptom onset and blood sampling.
In contrast to previous studies, our sampling protocol allowed for
determination of CRP changes across injured and non-injured myo-
cardium, and we found a decrease in CRP in both subgroups. This de-
monstrates that non infarcted myocardium is involved in the CRP
physiology as well. In support of this observation is an imaging study
that showed that high increases in CRP concentration after suffering MI
resulted in larger adjacent peri-infarct zones [29]. Interestingly, in a
murine study of ischemia and reperfusion, the impact of CRP injections
was studied in a controlled design. In the group with injections of CRP,
higher rates of apoptosis were not confined to the infarcted part of the
myocardium but included the entire area at risk [30]. In addition, in a
transgenic mouse model of MI, there was increased macrophage in-
filtration and apoptosis in the border zones of the infarcted myo-
cardium in the mice with CRP expression [31]. Importantly, an adverse
effect on left ventricular function recovery was observed in the mice
with versus without CRP expression, despite equal infarct sizes [31].
Therefore, our observation of a decrease in CRP over non-injured
myocardium, might be the first in vivo proof of a pathobiological role
for CRP in non-infarcted myocardium.
4.1. Implications
Our observations support the hypothesis that CRP binds to myo-
cardial cells in the setting of a NSTEMI. This opens new insights in the
role of inflammation in the aftermath of MI. New drugs targeting up-
stream biomarkers, interacting with the interleukin-CRP axis, are in-
vestigated in patients with stable cardiovascular disease (CIRT trial and
CANTOS trial) [32–34]. Their target is to slow down the progression of
coronary artery disease. In view of the potential roles of CRP in LV
remodelling after MI, it remains to be answered whether and how these
drugs might interfere with infarct healing. Interestingly, it was shown
that the IL-6 receptor antagonist tocolizumab reduced the levels of CRP,
and cardiac troponin release after NSTEMI [35]. Notably, together with
our findings of a trans-cardiac CRP decrease across the myocardium in
the acute phase of myocardial infarction, the concept that more insight
in the role of inflammatory processes after ACS might provide novel
therapeutic targets is strongly supported [36,37].
4.2. Limitations
Appreciating the mechanistic design of the study, our sample size is
limited and therefore results on trans-lesional findings, subgroup ana-
lyses, and correction for confounders may have been hampered by lack
of statistical power. The present study question concerns a pro-
spectively defined secondary analysis of the TRAMICI protocol, and the
primary outcome measure was the within patient difference in the
trans-cardiac gradient of CRP. In retrospect, incorporation of more
upstream inflammatory biomarkers (e.g. IL-1 and IL-6) would have
been interesting to gain additional information on the pathobiology of
inflammatory processes in acute myocardial infarction. The observed
absence of a trans-lesional CRP difference might have been caused by
local catabolism or uptake of CRP in the vessel wall [8]. However, the
CRP assay used has high-sensitivity characteristics. Thus, small differ-
ences were detectable, even in the setting of relatively high systemic
production. Despite several protocol driven precautions, it can not be
ruled out completely that dilution may have affected the observed
trans-cardiac decrease in CRP in some cases, to some extent. However,
prior to actual sampling, the protocol not only dictated a temporal halt,
to allow for sufficient blood reflux; it also incorporated a first sample of
3–4mL for blood gas analysis, before the sample of interest was ob-
tained. To further address this issue, we performed analyses on other
plasma proteins, i.e. albumin. In the absence of a per-patient correlation
between the trans-cardiac gradients of albumin and CRP, it is unlikely
that sample diluton markedly affected our findings. With regard to
possible confounders, none were identified for the trans-cardiac CRP
gradient. In addition, no difference in trans-cardiac gradient was ob-
served for patients on long-term aspirin and statin use. Finally, our
study lacks a control group of patients without evidence of MI. Ap-
preciating the different studies reporting no CRP gradient in patients
with stable angina [10,13,14,16], and the expected additional clinical/
scientific benefit in this particular group of patients, we decided not to
expose these patients to an invasive, rather extended procedure with an
elaborate sampling protocol.
4.3. Conclusion
In the present population of patients with ongoing NSTEMI, we
observed a net trans-cardiac CRP decrease in conjunction with increases
of CRP in the systemic circulation over time, without evidence of local
production at the site of the culprit coronary lesion suggesting myo-
cardial uptake of CRP. Due to elaborate blood sampling from both the
systemic and cardiac circulation, we were able to observe that CRP
uptake was not limited to the infarcted myocardium but was also pro-
minent in regions adjacent to injured myocardium.
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